BIOMAT Database Logo BIOMAT Database Logo

Proarrhythmic effects of anti-arrhythmic agents. 1994

A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
Department of Cardiology, Hospital de la Santa Creu/Sant Pau, University of Barcelona, Sant Antoni M. Claret, Spain.

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D001919 Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK. Bradyarrhythmia,Bradyarrhythmias,Bradycardias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D015716 Electrocardiography, Ambulatory Method in which prolonged electrocardiographic recordings are made on a portable tape recorder (Holter-type system) or solid-state device ("real-time" system), while the patient undergoes normal daily activities. It is useful in the diagnosis and management of intermittent cardiac arrhythmias and transient myocardial ischemia. Ambulatory Electrocardiography,Electrocardiography, Dynamic,Electrocardiography, Holter,Holter ECG,Holter EKG,Holter Monitoring,Monitoring, Ambulatory Electrocardiographic,Monitoring, Holter,Ambulatory Electrocardiography Monitoring,Dynamic Electrocardiography,Electrocardiography Monitoring, Ambulatory,Holter Electrocardiography,Ambulatory Electrocardiographic Monitoring,ECG, Holter,ECGs, Holter,EKG, Holter,EKGs, Holter,Electrocardiographic Monitoring, Ambulatory,Holter ECGs,Holter EKGs,Monitoring, Ambulatory Electrocardiography
D016171 Torsades de Pointes A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute, and QRS complexes with changing amplitude and twisting of the points. The term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long QT intervals exceeding 500 milliseconds or BRADYCARDIA. Torsades de pointes may be self-limited or may progress to VENTRICULAR FIBRILLATION. Torsade de Pointes,Pointes, Torsade de,Pointes, Torsades de,de Pointes, Torsade,de Pointes, Torsades
D016757 Death, Sudden, Cardiac Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005) Cardiac Sudden Death,Sudden Cardiac Death,Cardiac Arrest, Sudden,Sudden Cardiac Arrest,Arrest, Sudden Cardiac,Cardiac Arrests, Sudden,Cardiac Death, Sudden,Death, Cardiac Sudden,Death, Sudden Cardiac,Sudden Death, Cardiac
D017180 Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). Idiopathic Ventricular Tachycardia,Nonsustained Ventricular Tachycardia,Paroxysmal Supraventricular Tachycardia,Ventricular Tachyarrhythmias,Ventricular Tachycardia,Idiopathic Ventricular Tachycardias,Nonsustained Ventricular Tachycardias,Paroxysmal Supraventricular Tachycardias,Supraventricular Tachycardia, Paroxysmal,Tachyarrhythmia, Ventricular,Tachycardia, Idiopathic Ventricular,Tachycardia, Nonsustained Ventricular,Tachycardia, Paroxysmal Supraventricular,Ventricular Tachyarrhythmia,Ventricular Tachycardia, Idiopathic,Ventricular Tachycardia, Nonsustained,Ventricular Tachycardias

Related Publications

A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Proarrhythmic effects of anti-arrhythmia agents].
April 1990, Deutsche medizinische Wochenschrift (1946),
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Proarrhythmic effects of anti-arrhythmia agents].
January 1995, La Revue de medecine interne,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Proarrhythmic effects of anti-arrhythmia agents].
August 1998, Revue medicale de la Suisse romande,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Side effects of anti-arrhythmic agents].
October 1971, Klinicheskaia meditsina,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Anti-arrhythmic and cardiodepressive effects of anti-arrhythmia agents].
January 1988, Zeitschrift fur Kardiologie,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[The pro-arrhythmic effects of anti-arrhythmia agents].
January 1994, Zeitschrift fur Kardiologie,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Anti-arrhythmic agents. 1. anti-arrhythmic agents, indications, counter-indications side effects; dosage, methods of application; differential therapy].
April 1980, Fortschritte der Medizin,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Pro-arrhythmic effects of anti-arrhythmic agents. Study methods and difficulties in analysis].
January 1992, Therapie,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Anti-arrhythmic agents. 2. Special anti-arrhythmic effect, known drug interactions].
April 1980, Fortschritte der Medizin,
A Bayés de Luna, and J Guindo, and R Elosua, and X Viñolas, and A Bayés-Genis, and J Sobral, and J Sztajzel, and S Boveda
[Pro-arrhythmic effects of anti-arrhythmic preparations].
October 1991, Kardiologiia,
Copied contents to your clipboard!